Cellular pharmacology of D-d4FC, a nucleoside analogue active against drug-resistant HIV

Antiviral Chemistry and Chemotherapy

Volumn 14, Issue 1, 2003, Pages 39-47

  Erickson Viitanen, Susan ^a   Wu, Jing Tao ^a   Shi, Guoen ^a   Unger, Steven ^a   King, Robert W ^a   Fish, Barbara ^a   Klabe, Ronald ^a   Geleziunas, Romas ^a   Gallagher, Karen ^a   Otto, Michael J ^b   Schinazi, Raymond F ^c  

^a DUPONT COMPANY   (United States)

^b PHARMASSET INC   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Combination therapy; Intracellular phosphorylation; Nucleoside analogue

Indexed keywords

6 CHLORO 4 (2 CYCLOPROPYLVINYL) 3,4 DIHYDRO 4 TRIFLUOROMETHYL 2(1H) QUINAZOLINONE; ABACAVIR; BETA DEXTRO 2',3' DIDEOXY 2',3' DIDEHYDRO 5 FLUOROCYTIDINE; BETA DEXTRO 2',3' DIDEOXY 2',3' DIDEHYDRO 5 FLUOROCYTIDINE TRIPHOSPHATE; CYTIDINE DERIVATIVE; DIDANOSINE; EFAVIRENZ; ELVUCITABINE; LAMIVUDINE; LAMIVUDINE TRIPHOSPHATE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE DERIVATIVE; NUCLEOSIDE TRIPHOSPHATE; PHYTOHEMAGGLUTININ; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CELL STIMULATION; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG UPTAKE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; IN VITRO STUDY; MONONUCLEAR CELL; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; VIRUS REPLICATION; VIRUS RESISTANCE;

EID: 12444267896     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020301400104     Document Type: Article

References (39)

1. Bridges EG, Dutschman GE, Gullen EA & Cheng YC (1996) Favorable interaction of β-L-nucleoside analogues with clinically approved anti HIV nucleoside analogues for the treatment of human immunodeficiency virus. Biochemical Pharmacology 51:731-736.
2. Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schecter M, Schooley RT, Thompson MA, Vella S, Yeni PG & Volberding PA (2000) Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA panel. Journal of the American Medical Association 283:381-390.
3. Chou TC & Talalay P (1984) Quantitative analysis of dose-effect relationships, the combined effects of multiple drugs or enzyme inhibitors. Advances in Enzyme Regulation 22:27-55.
4. Coakley EP, Gillis JM & Hammer SM (2000) Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine. AIDS 14:F9-F15.
5. Corbett JW, Ko SS, Rodgers JD, Jeffrey S, Bacheler LT, Klabe RM, Diamond S, Lai CM, Rabel SR, Saye JA, Adams SP, Trainor GL, Anderson PS & Erickson-Viitanen S (1999) Expanded spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1. Antimicrobial Agents & Chemotherapy 43:2893-2897.
6. Daluge S, Good S, Faletto M, Miller W, St. Clair M, Boone L, Tisdale M, Parry N, Reardon J, Dornsife R, Averett D & Krenitsky T (1997) 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrobial Agents & Chemotherapy 41:1082-1093.
7. Dutschman GE, Bridges EG, Liu SH, Gullen E, Guo X, Kukhanova M & Cheng YC (1998) Metabolism of 2′,3′-dideoxy2′,3′-didehydro-β-L-(-) 5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus β-D-(+) nucleoside analogs in vitro. Antimicrobial Agents & Chemotherapy 42:1799-1804.
8. Bondoc LL Jr, Shannon WM, Secrist JA 3rd, Vince R & Fridland A (1990) Metabolism of the carbocyclic nucleoside analogue carbovir, an inhibitor of human immunodeficiency virus, in human lymphoma cells. Biochemistry 29:9839-9843.
9. Furman PA, Fyle JA, St Clair MH, Weinhold K, Rideout JL, Freeman GA, Nusinoff-Lehrman S, Bolognesi DP, Broder S, Mitsuya H & Barry DW (1986) Phosphorylation of 3′-azido-3′deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proceedings of the National Academy of Sciences, USA 83:8333-8337.
10. Gao WY, Agbaria R, Driscoll JS & Mitsuya H (1994) Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2′,3′-dideoxynucleoside analogs in resting and activated human cells. Journal of Biological Chemistry 269:12633-12638.
11. Geleziunas R, Gallagher K, Zhang HC, Bacheler LT, Garber S, Wu JT, Shi G, Otto MJ, Schinazi RF & Erickson-Viitanen S (2003) HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor D-d4FC. Antiviral Chemistry & Chemotherapy 14:49-59.
12. Havlir DV, Tierney C, Friedland GH, Pollard RB, Smeaton L, Sommadossi JP, Fox L, Kessler H, Fife KH & Richman DD (2000) In vivo antagonism with zidovudine and stavudine in combination. Journal of Infectious Diseases 174:671-672.
13. Hertogs K, Bloor S, DeVroey V, van Den Eynde C, Dehertogh P, van Cauwenberge A, Sturmer M, Alcorn T, Wegner S, van Houtte M, Miller V & Larder BA (2000) A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V. Antimicrobial Agents & Chemotherapy 44:568-573.
14. Hirsch MS (2002) HIV drug resistance - a chink in the armor. New England Journal of Medicine 347:438-439.
15. Ho TH & Hitchcock MJM (1989) Cellular pharmacology of 2′,3′dideoxy-2′,3′-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus. Antimicrobial Agents & Chemotherapy 33:844-849.
16. Hoggard PG, Kewn S, Barry MG, Khoo SH & Back DJ (1997) Effects of drugs on 2′,3′-dideoxy-2′,3′- didehydrothymidine phosphorylation in vitro. Antimicrobial Agents & Chemotherapy 41:1231-1236.
17. Johnson MA, Ahluwalia G, Connelly MC, Cooney DA, Broder S, Johns DG & Fridland A (1988) Metabolic pathways for the activation of the antiretroviral agent 2′,3′-dideoxyadenosine in human lymphoid cells. Journal of Biological Chemistry 263:15354-15357.
18. Johnson MA & Fridland A (1989) Phosphorylation of 2′,3′dideoxyinosine by cytosolic 5′-nucleotidase of human lymphoid cells. Molecular Pharmacology 36:291-295.
19. Johnson MA, Johns DG & Fridland A (1987) 2′,3′Dideoxynucleoside phosphorylation by deoxycytidine kinase from normal human thymus extracts: activation of potential drugs for AIDS therapy. Biochemical & Biophysical Research Communications 148:1252-1258.
20. King RW, Klabe RM, Reid CD & Erickson-Viitanen SK (2002) Potency of nonnucleoside reverse transcriptase inhibitors (NNRTIs) used in combination with other human immunodeficiency virus NNRTIs, NRTIs or protease inhibitors. Antimicrobial Agents & Chemotherapy 46:1640-1646.
21. Merrill DP, Moonis M, Chou TC & Hirsch MS (1996) Lamivudine or stavudine in two and three drug combinations against human immunodeficiency virus type 1 replication in vitro. Journal of Infectious Diseases 173:355-364.
22. Moore KHP, Barrett JE, Shaw S, Pakes GE, Churchus R, Kapoor A, Lloyd J, Barry MG & Back D (1999) The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1. AIDS 13:2239-2250.
23. Murphy RL, Schurmann D, Kravec I, Eron J, Havlir D, Beard A, Cartee L, Hurwitz SJ, Erickson-Viitanen S, Liotta DC, Schinazi RF & Otto MJ (2002) Pharmacokinetics and safety of the nucleoside Reverset in HIV-1 infected patients. HIV Dart 2002, December 15-19, Naples, Fla., USA.
24. O'Brien WA (2000) Resistance against reverse transcriptase inhibitors. Clinical Infectious Diseases 30(Suppl. 2):185-192.
25. Palmer S & Cox S (1994) Intracellular metabolism of 3′-azido-3′deoxythymidine and 2′,3′-dideoxyinosine in combination in the absence and presence of ribavirin. Antiviral Chemistry & Chemotherapy 5:403-409.
26. Pastor-Anglada M, Felipe A & Casado FJ (1998) Transport and mode of action of nucleoside derivatives used in chemical and antiviral therapies. Trends in Pharmaceutical Sciences 19:424-430.
27. Pollard RB, Tierney C, Havlir D, Tebas P, Fox L, Smeaton L, Richman D & Friedland GH (2002) A Phase II randomized study of the virologic and immunologic effect of zidovudine + stavudine versus stavudine alone and zidovudine + lamivudine in patients with 300 CD4 cells who were antiretroviral naive (ACTG 298). AIDS Research & Human Retroviruses 18:699-704.
28. Rodriguez JF, Rodriguez JL, Santana J, Garcia H & Rosario O (2000) Simultaneous quantitation of intracellular zidovudine and lamivudine triphosphates in human immunodeficiency virusinfected individuals. Antimicrobial Agents & Chemotherapy 44:3097-3100.
29. Schinazi RF (1991) Combined therapeutic modalities for viral infections - rationale and clinical potential. In Synergism and Antagonism in Chemotherapy, pp. 110-181. Edited by T-C Chou & DC Rideout. Orlando, FL: Academic Press.
30. Schinazi RF, Larder BA & Mellors JW (2001) Mutations in retroviral genes associated with drug resistance: 2000-2001 update. International Antiviral News 8:65-81.
31. Schinazi RF, Mellors J, Bazmi H, Diamond S, Garber S, Gallagher K, Geleziunas R., Klabe R., Pierce M, Rayner M, Wu JT, Zhang H, Hammond J, Bacheler L, Manion DJ, Otto MJ, Stuyver L., Trainor G, Liotta DC & Erickson-Viitanen S (2002) DPC 817: a cytidine nucleoside analog with activity against zidovudine-and lamivudine-resistant viral variants. Antimicrobial Agents & Chemotherapy 46:1394-1401.
32. Shi G, Wu JT, Li Y, Geleziunas R, Gallagher K, Emm T, Olah T & Unger S (2002) Novel direct detection method for quantitative determination of intracellular nucleoside triphosphates using weak anion exchange liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry 16:1092-1099.
33. Smallheer JM, Otto MJ, Amarl-Ly CA, Earl RA, Myers MJ, Pennev P, Montefiori DC & Wuonola MA (1993) Synthesis and antiHIV activity of a series of 2-indolinones and related analogs. Antiviral Chemistry & Chemotherapy 4:27-39.
34. Sommadossi JP (1998) Pharmacological considerations in antiretroviral therapy. Antiviral Therapy 3:9-12.
35. Stein DS & Moore KHP (2001) Phosphorylation of nucleoside analog antiretrovirals: a review for clinicians. Pharmacotherapy 21:11-34.
36. Tornavik Y, Jacobsson B, Britton S & Eriksson S (1991) Intracellular metabolism of 3′-azidothymidine in isolated human peripheral blood mononuclear cells. AIDS Research & Human Retroviruses 7:751-759.
37. Van Vaerenbergh K, Van Laethem K, Albert J, Boucher CA, Clotet B, Floridia M, Gerstoft J, Hejdeman B, Nielsen C, Pannecouque C, Perrin L, Pirillo MF, Ruiz L, Schmit JC, Schneider F, Schoolmeester A, Schurman R, Stellbrink HJ, Stuyver L, Van Lunzen J, Van Remoortel B, Van Wijngaerden E, Vella S, Witvrouw M, Yerly S, DeClercq E, Destmyer J & Vandamme AM (2000) Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues. Antimicrobial Agents & Chemotherapy 44:2109-2117.
38. Veal CJ, Hoggard PG, Barry MG, Khoo S & Back DJ (1996) Interaction between lamivudine and other nucleoside analogues for intracellular phosphorylation. AIDS 10:546-548.
39. Zhu QY, Scarborough A, Polsky B & Chou TC (1996) Drug combinations and effect parameters of zidovudine, stavudine and nevirapine in standardized drug-sensitive and resistant HIV type 1 strains. AIDS Research & Human Retroviruses 12:507-617.